MICA and cancer: Wucherpfennigand co-workers, for example, selected antibodies to selectively blockthe proteolytic shedding of MICA/B, a T-cell and NK cell ligand thatis highly shed from many cancer cells so that they can avoid immunerecognition.361 Likewise, vaccine-generatedantibodies can also block the MICA/B shedding, and may provide a promisingapproach for cancer vaccines.